Immatics N.V. (NASDAQ:IMTX)
| Market Cap | $863.40M-45.6% |
| Revenue (ttm) | $43.44M-48.7% |
| Net Income | -$232.03M-100.2% |
| EPS | -$1.67-92.0% |
| Shares Out | 149.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 746,747 |
| Open | $5.91 |
| Previous Close | $5.95 |
| Day's Range | $5.71 - $5.95 |
| 52-Week Range | $5.71 - $12.41 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | $17.67(+206.24%) |
| Earnings Date | Mar 4, 2027 |
About IMTX
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Immatics N.V. Stock Analysis — InsiderScore
Immatics N.V. scored higher than 8% of companies evaluated by InsiderBuying, and ranked 84th out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Immatics N.V. bought $7.50 million of stock across 1 purchase in the last 90 days, the largest of them $7.50 million.
The average purchase added about 8% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$IMTX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IMTX
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $1.21M |
| KOMPState Street SPDR S&P Kensho New Economies Composite ETF | $1.10M |
| SBIOALPS Medical Breakthroughs ETF | $1.06M |
| CANCTema Oncology ETF | $860.00K |
| ONEQFidelity Nasdaq Composite Index ETF | $368.64K |
| GWXState Street SPDR S&P International Small Cap ETF | $345.31K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from IMTX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings missed revenue estimates with net loss expansion; mixed outlook on stock performance potential despite expectations.
Recent Insider Activity
Insider Score Trend Over Time
+12.7 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.65% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.64% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.53% |
| CANC | Tema Oncology ETF | 0.45% |
| TSEE | T. Rowe Price Small Cap ETF | 0.26% |
| KOMP | State Street SPDR S&P Kensho New Economies Composite ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
